In 2014, U.S. Food and Drug Administration also approved the marketing of NephroCheck, a test based on the arithmetic result of the concentrations of urinary TIMP2 and IGFBP7 ([TIMP2]*[IGFBP7]), although its diagnostic ability for septic AKI is not optimal 20. Here, IGFBP7 is linked to acute kidney injury.